【摘要】 目的评价心肌康方案对降低病毒性心肌炎急性期患者心肌肌钙蛋白Ⅰ(cTnI)和血清肌酸激酶同工酶(CK-MB)水平的疗效。方法就诊的161例符合纳入标准,且不符合排除标准的病毒性心肌炎急性期患者,随机分为治疗组和对照组。治疗组在基础措施上加用心肌康方案,对照组在基础措施上加用西药常规治疗30 d。观察并记录患者CK-MB和cTnI的值,应用统计方法,分析心肌康方案对CK-MB和cTnI值变化的影响。结果两组治疗前、治疗第30天cTnI正常率组间、组间、差值组间、组内比较,均无统计学差异(P>0.05)。两组治疗前、治疗第30天CK-MB正常率组间、组间比较、差值组间比较,均无统计学差异(P>0.05)。组内比较,试验组有统计学差异(P<0.05),对照组无统计学差异(P>0.05)。结论心肌康方案可有效降低CK-MB和cTnI值。更多还原

【Abstract】 AIM To investigate the effect of Xinjikang program on the reduction in cTnI and CK-MB levels in patients with acute viral myocarditis.METHODS Coincided and non-excluded with the enrolled standard,altogether one hundred and sixty-one patients were randomly divided into treatment group and control group.Both groups accepted the traditional physician therapy,but the treatment group was added by Xinjikang program.Course of treatment was 30 days.Levels of CK-MB and cTnI were analyzed and recorded.RESULTS There were no significant differences in levels of CK-MB and cTnI between and within groups before and after the treatment(P>0.05),except CK-MB within groups(P<0.05).CONCLUSION Xinjikang program can effectively reduce levels of CK-MB and cTnI related to creatine kinase isoenzyme.更多还原